A phase I/II trial of trastuzumab and gefitinib in patients with metastatic breast cancer that overexpresses HER2/neu (ErbB-2)

Clinical Breast Cancer

Volumn 4, Issue 2, 2003, Pages 142-145

  Moulder, Stacy L ^a   Arteaga, Carlos L ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Combined therapy; EGFR; Small molecule inhibitors; ZD1839

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; ONCOPROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; TYROSINE;

ADULT; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER PATIENT; CANCER SURVIVAL; CELL PROLIFERATION; CELL VIABILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DRUG HALF LIFE; DRUG RESPONSE; DRUG SELECTIVITY; DRUG WITHDRAWAL; DRY SKIN; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HEADACHE; HEART DISEASE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; METASTASIS POTENTIAL; NAUSEA AND VOMITING; ONCOGENE NEU; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROTEIN PHOSPHORYLATION; PROTO ONCOGENE; RASH; RECEPTOR BLOCKING; TREATMENT OUTCOME;

EID: 0041696766     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2003.n.020     Document Type: Article

References (21)

1. Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992; 89:4285-4289.
2. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-2648.
3. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-over-expressing metastatic breast cancer. J Clin Oncol 2002; 20:719-726.
4. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpression HER2. N Engl J Med 2001; 344:792.
5. Fry DW, Bridges AJ, Denny WA, et al. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc Natl Acad Sci U S A 1998; 95:12022-12027.
6. Toledo LM. Lydon NB, Elbaum D. The structure-based design of ATP-site directed protein kinase inhibitors. Curr Med Chem 1999; 6:775-805.
7. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001; 19:32S-40S.
8. Bos M, Mendelsohn J, Kim YM, et al. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res 1997; 3:2099-2106.
9. Moulder SL, Yakes FM, Muthuswamy SK, et al. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001; 61:8887-8895.
10. Moasser MM, Basso Averbuch SD, et al. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signalling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 2001; 61:7184-7188.
11. Anderson NG, Ahmad T, Chan K, et al. ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int J Cancer 2001; 94:774-782.
12. Harris AL, Nicholson S, Sainsbury JR, et al. Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu. J Steroid Biochem 1989; 34:123-131.
13. Nicholson RI, McClelland RA, Finlay P, et al. Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer 1993; 29A:1018-1023.
14. Ye D, Mendelsohn J, Fan Z. Augmentation of a humanized anti-HER2 mAb 4d5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene 1999; 18:731-738.
15. Arteaga CL, Ramsey TT, Shawver LK, et al. Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site. J Biol Chem 1997; 272:23247-23254.
16. Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signalling with potential for cancer therapy. Cancer Res 2002; 62:5749-5754.
17. Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002; 20:2240-2250.
18. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14:737-744.
19. Albanell J, Rojo F, Averbuch S, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002; 20:110-124.
20. Thor AD, Liu S, Edgerton S, et al. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. J Clin Oncol 2000; 18:3230-3239.
21. DiGiovanna MP, Chu P, Davidson TL, et al. Active signalling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ: clinicopathological correlates. Cancer Res 2002; 62:6667-6673.